Regression of lymphomatous skin deposits in a chronic lymphocytic leukemia patient treated with the Toll-like receptor-7/8 agonist, imiquimod

Leuk Lymphoma. 2005 Jun;46(6):935-9. doi: 10.1080/10428190500054426.

Abstract

The identification of clinically relevant, active immunomodulatory agents is important for developing immunotherapeutic approaches to chronic lymphocytic leukemia (CLL) and other B-cell lymphomas that are not curable with conventional chemotherapy. In this investigation, the imidazoquinoline Toll-like receptor (TLR)-7/8 agonist, imiquimod, was found to mediate the clearance of a lymphomatous skin lesion in a CLL patient. Imidazoquinolines also activated TLR-7/8 signaling pathways, resulting in increased expression of costimulatory molecules on circulating tumor cells. These observations extend the therapeutic spectrum of imiquimod to cutaneous B-cell lymphomas and suggest the use of TLR-7/8 agonists in CLL immunotherapy.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aminoquinolines / therapeutic use*
  • Antineoplastic Agents / therapeutic use*
  • Disease Progression
  • Humans
  • Imiquimod
  • Immunotherapy / methods
  • Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
  • Leukemia, Lymphocytic, Chronic, B-Cell / pathology
  • Lymphoma / drug therapy*
  • Lymphoma / pathology
  • Male
  • Signal Transduction
  • Skin Neoplasms / drug therapy*
  • Skin Neoplasms / pathology
  • Toll-Like Receptor 7 / agonists*
  • Toll-Like Receptor 8 / agonists*
  • Treatment Outcome

Substances

  • Aminoquinolines
  • Antineoplastic Agents
  • TLR7 protein, human
  • TLR8 protein, human
  • Toll-Like Receptor 7
  • Toll-Like Receptor 8
  • Imiquimod